HomeProductsBioactive CompoundsImmunology & InflammationImmunology & Inflammation RelatedIberdomide
Chemical structure of CAS 1323403-33-3

Iberdomide

CAS No.1323403-33-3
MDL No.N/A
MFC25H27N3O5
MW449.50
InChI KeyIXZOHGPZAQLIBH-NRFANRHFSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1323403-33-3
Product NameIberdomide

Biological Targets

CRBN·DDB1·CUL4A·RBX1

Associated Conditions

asymptomatic myeloma·multiple myeloma·lymphoma·follicular lymphoma·sarcoidosis·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.

Journal of medicinal chemistry • Vol. 61, Issue 2 • 2018
PMID: 28425720DOI: 10.1021/acs.jmedchem.6b01921

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.

Blood cancer journal • Vol. 5, Issue 10 • 2015
PMID: 26430725PMC: PMC4635186DOI: 10.1038/bcj.2015.66

Association between polymorphisms of the IKZF3 gene and systemic lupus erythematosus in a Chinese Han population.

PloS one • Vol. 9, Issue 10 • 2014
PMID: 25271777PMC: PMC4182708DOI: 10.1371/journal.pone.0108661

Documentation

Similar Products